300142.SHE Walvax BioTech
- Market cap
- CNY 17.8B
- P/E
- 1,113.0x
- P/B
- 2.51x
- ROE
- 0.1%
- Dividend yield
- 0.16%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300142.SHE undervalued?
Graham numberThe Graham number of Walvax BioTech cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Walvax BioTech fundamental analysis
No fundamental analysis for Walvax BioTech yet.
Walvax BioTech stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Walvax BioTech
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conju…
Full company profileWalvax BioTech financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Walvax BioTech annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 591M | 668M | 874M | 1.12B | 2.94B | 3.46B | 5.09B | 4.11B | 2.82B | 2.41B | 1.53B |
| Gross Profit | 272M | 448M | 692M | 886M | 2.53B | 3.06B | 4.41B | 3.36B | 2.08B | 1.66B | 1.02B |
| Operating Income | -160M | -144M | 132M | 233M | 1.38B | 710M | 1.10B | 614M | 96.7M | 70.0M | 77.0M |
| EBITDA | -12.0M | 16.4M | 242M | 248M | 1.15B | 928M | 1.42B | 1.12B | 388M | 482M | 67.9M |
| Net Income | 70.5M | -537M | 1.05B | 142M | 1.00B | 428M | 729M | 419M | 142M | 178M | 10.0M |
| EPS | 0.05 | -0.35 | 0.68 | 0.09 | 0.65 | 0.27 | 0.45 | 0.26 | 0.09 | 0.11 | 0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 6.32B | 5.88B | 7.24B | 7.02B | 9.65B | 13.7B | 15.3B | 15.6B | 14.7B | 12.1B | 10.4B |
| Total Liabilities | 2.80B | 2.32B | 1.98B | 1.35B | 1.80B | 3.68B | 4.35B | 4.19B | 3.22B | 2.26B | 3.16B |
| Shareholders' Equity | 3.21B | 3.03B | 4.58B | 4.87B | 6.54B | 8.48B | 9.08B | 9.35B | 9.43B | 8.62B | 6.93B |
| Cash & Short-term Investments | 1.42B | 1.21B | 2.48B | 2.38B | 1.96B | 3.44B | 3.87B | 4.36B | 3.76B | 1.35B | 907M |
| Total Debt | 280M | 476M | 211M | - | 42.0M | 311M | 439M | 776M | 445M | 427M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -89.9M | -10.1M | -65.2M | 62.0M | 114M | 705M | 1.20B | 1.13B | 1.04B | 494M | - |
| Capital Expenditure | 250M | 331M | 227M | 352M | 407M | 1.10B | 1.09B | 946M | 550M | 510M | 299M |
| Free Cash Flow | -340M | -388M | -293M | -290M | -293M | -398M | 110M | 188M | 486M | -15.2M | 172M |
| Ratios | |||||||||||
| ROE | 2.2% | -17.7% | 22.8% | 2.9% | 15.3% | 5.0% | 8.0% | 4.5% | 1.5% | 2.1% | 0.1% |
| ROA | 1.1% | -9.1% | 14.4% | 2.0% | 10.4% | 3.1% | 4.8% | 2.7% | 1.0% | 1.5% | 0.1% |
| Net Profit Margin | 11.9% | -80.4% | 119.7% | 12.7% | 34.1% | 12.4% | 14.3% | 10.2% | 5.0% | 7.4% | 0.7% |
| Debt to Equity | 0.09x | 0.16x | 0.05x | - | 0.01x | 0.04x | 0.05x | 0.08x | 0.05x | 0.05x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Walvax BioTech dividends
- Dividend yield
- 0.16%
- Forward dividend
- 0.16 CNY
- Payout ratio
- 16.3%
- Ex-dividend date
- Jun 24, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 29.0M | 0.02 | 16.3% |
| 2024 | CNY 40.9M | 0.03 | 28.8% |
| 2023 | CNY 16.0M | 0.01 | 3.8% |
| 2022 | CNY 50.1M | 0.03 | 6.9% |
| 2021 | CNY 78.3M | 0.05 | 18.3% |
| 2020 | CNY 30.9M | 0.02 | 3.1% |
| 2019 | CNY 68.7M | 0.04 | 48.4% |
| 2018 | CNY 4.45M | 0.00 | 0.4% |
| 2017 | CNY 34.3M | 0.02 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 30:10 on Oct 14, 2015.
Who owns Walvax BioTech
- Insiders 9.58%
- Institutions 10.10%
- Public & others 80.31%
- Shares outstanding 1.60B
- Free float 1.48B
Walvax BioTech company profile
- Company name
- Walvax BioTech
- Ticker
- 300142.SHE
- ISIN
- CNE100000WN2
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Nov 12, 2010
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,981
- Fiscal year end
- December
- Address
- No. 395 Kexin Road, Kunming, China, 650101
- Phone
- 86 87 1683 30860
- Website
- walvax.com
About Walvax BioTech
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The company was founded in 2001 and is headquartered in Kunming, China.
Walvax BioTech management
8- Mr. Wei YaoPresident & Director · born 1972
- Dr. Shaozhong DongVice Chairman & VP · born 1968
- Mr. Changxiong WuAccounting Supervisor & CFO · born 1983
- Ms. Yun Yan WuDirector of Operations · born 1982
- Mr. Qingtang DuanEngineering Director · born 1982
- Mr. Ming Bo SunVP & Director · born 1969
- Mr. Ye YanVP & Board Secretary · born 1984
- Ms. Wei LiVice President · born 1987